Table_1_Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review.docx

Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein–Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer–cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months.

肝内淋巴上皮样胆管癌（LELCC）是一种起源于胆管上皮的极为罕见的恶性肿瘤。截至目前，关于LELCC的影像学特征、临床病理学特征及治疗方式的研究尚显不足，全球范围内报告的无Epstein-Barr病毒（EBV）感染的LELCC病例不足28例。LELCC的治疗策略尚未得到充分探索。本研究中，我们呈现了两例无EBV感染的LELCC患者的病例，患者接受了肝切除术、化疗及免疫治疗，并取得了较长的生存期。患者接受了手术以切除肿瘤，随后实施了辅助化疗，采用GS方案，并进行了包括自然杀伤细胞-细胞因子诱导的杀伤细胞（NK-CIK）和尼伏单抗在内的联合免疫治疗。两位患者均预后良好，生存时间超过100个月和85个月。